Luminex Company Profile

18:03 EDT 20th September 2018 | BioPortfolio

Luminex Corporation was incorporated in May 1995 and began commercial production of our first generation system in 1997. Luminex® (NASDAQ: LMNX) develops, manufactures and markets innovative biological testing technologies with applications throughout the life-sciences industry. The company’s open-architecture xMAP® technology enables large numbers of biological tests (bioassays) to be conducted and analyzed quickly, cost-effectively and accurately.Systems using xMAP technology (formerly known as LabMAP®) perform discrete bioassays on the surface of color-coded beads known as microspheres, which are then read in a compact analyzer. Using lasers and high-speed digital-signal processors, the analyzer simultaneously identifies the bioassay and measures the results, all in real time.


12212 Technology Blvd
United States of America


Phone: 512.219.8020 or 888.219.8020
Fax: 512.219.5195

News Articles [14 Associated News Articles listed on BioPortfolio]

BioRad Bio Plex Luminex 100 Luminex XYP Array System

$0.99 (0 Bids)End Date: Saturday Apr-14-2018 18:19:09 PDTBid now | Add to watch list Biotech365 : BioRad Bio Plex Luminex 100 Luminex XYP Array System BioMarketplace You want to propose your prod...

Bio-Rad Luminex 100 XYP SD Multiplexing Analyzer Sheath Delivery System

EUR 563.18End Date: Thursday Jun-7-2018 23:18:56 ISTBuy It Now for only: EUR 563.18Buy It Now | Add to watch list Biotech365 : Bio-Rad Luminex 100 XYP SD Multiplexing Analyzer Sheath Delivery Sys...

Luminex kündigt Dividende für das dritte Quartal an

Das amerikanische Biotechnologieunternehmen Luminex Corporation (ISIN: US55027E1029, NASDAQ: LMNX) wird seinen Aktionären für das dritte Quartal eine Dividende von 0,06 US-Dollar je Aktie ausbezahl....

Luminex starts clinical trials for VERIGENE II gastrointestinal assay

Luminex has started clinical studies for the gastrointestinal (GI) assay on the VERIGENE II system.

Luminex Corporation (LMNX) CEO Homi Shamir on Q2 2018 Results - Earnings Call Transcript

Luminex Corporation's (LMNX) CEO Homi Shamir on Q1 2018 Results - Earnings Call Transcript

Luminex Corp LMNX Financial and Strategic SWOT Analysis Review [Report Updated: 08052018] Prices from USD $125

Luminex Corp LMNX Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData ...

Luminex Corp LMNX Product Pipeline Analysis, 2018 Update [Report Updated: 16052018] Prices from USD $750

SummaryLuminex Corp Luminex is a medical devices company which develops, manufactures and markets proprietary biological testing technologies. The company offers wide range of products including instr...

Drugs and Medications [0 Results]


PubMed Articles [20 Associated PubMed Articles listed on BioPortfolio]

Comparison of two Luminex Single-Antigen bead flow cytometry assays for detection of Donor Specific Antibodies after renal transplantation.

Defining the clinical relevance of Donor Specific HLA antibodies (DSA) detection by Luminex Single Antigen (LSA) flow beads assay is critical in monitoring posttransplant outcome.

The good, the bad and the ugly of luminex donor specific cross match.

The presence of donor specific antibodies directed against human leukocyte antigen significantly influences renal transplant due to antibody mediated rejection (AMR). We performed the screening of pre...

Sensitive detection of live Escherichia coli by bacteriophage amplification-coupled immunoassay on the Luminex® MAGPIX instrument.

Phages are natural predators of bacteria and have been exploited in bacterial detection because of their exquisite specificity to their cognate bacterial hosts. In this study, we present a "proof of c...

Class II Human Leukocyte Antigen Epitope Mismatch Predicts De Novo Donor-Specific Antibody Formation After Liver Transplantation.

Formation of de novo donor-specific antibodies (dn-DSAs) has been associated with longterm immunologic complications after liver transplantation (LT). We hypothesized that human leukocyte antigen (HLA...

Corrigendum to Monitoring native HLA-I trimer specific antibodies in Luminex multiplex single antigen bead assay: Evaluation of beadsets from different manufacturers Journal of Immunological Methods, Volume 450, Year (2017), start page 73, end page 80.

Clinical Trials [12 Associated Clinical Trials listed on BioPortfolio]

Cytokine Evaluation of Accelerated Tooth Movement

Gingival Crevicular Fluid samples will be collected using periopapers after accelerated tooth movement technique, results will be achieve with cytokine measurements that will be done using...

Fluency Stent-Graft Versus Luminex Stent for Angioplasty of Recurrent Stenosis of the Cephalic Arch in Autogenous Arteriovenous (AV) Access for Hemodialysis

The type of hemodialysis access and preservation of this access greatly influences the quality of life and survival of patients undergoing hemodialysis. The Kidney Disease Outcomes Quality...

Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects

This is a phase i randomized, double blind clinical trial designed to evaluate the safety, tolerability and immunogenicity of the ID93 recombinant protein antigen alone or formulated with ...

ZRx-101 (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia

The ZRx-101 cells have features similar to activated NK cells, but mediate superior anti-tumor activity against hematologic and solid tumor targets in vitro and in vivo. The utilization of...

An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects

This is a China registration study. A randomized, double-blind, placebo-controlled immunogenicity and safety study in Chinese female subjects aged 9 to 45 years and male subjects aged 9 to...

Companies [4 Associated Companies listed on BioPortfolio]


Luminex Corporation was incorporated in May 1995 and began commercial production of our first generation system in 1997. Luminex® (NASDAQ: LMNX) develops, manufactures and markets innovative biologic...

Luminex Corp.

Luminex Corporation

One Lambda Inc.

One Lambda Inc. is a world leader in the manufacture of HLA medical diagnostic products based in Canoga Park, California. The company is committed to develop products that improve...

More Information about "Luminex" on BioPortfolio

We have published hundreds of Luminex news stories on BioPortfolio along with dozens of Luminex Clinical Trials and PubMed Articles about Luminex for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Luminex Companies in our database. You can also find out about relevant Luminex Drugs and Medications on this site too.

Quick Search


Relevant Topic

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Corporate Database Quicklinks

Searches Linking to this Company Record